`
`Page 1 of2
`
`Korlym®
`(mifepristone)
`300 mg Tablets
`
`Korlym®
`•
`•
`1 epns one
`
`KORL YM PRESCRIBING
`
`INFORMATION, INCLUDING
`BOXED WARNING >
`
`300 mg Tablets
`
`KORLYM MEDICATION GUIDE >
`
`VISIT KORL YM.COM >
`
`View information about the Corcept Access & Financial Support and Patient Advocate
`
`Program for Korlym.
`
`https://www.corcept.com/product/
`
`Corcept Therapeutics, Inc.
`Exhibit 2001
`Neptune Generics, LLC v. Corcept Therapeutics, Inc.
`Case IPR2018-01494
`
`11/19/2018
`Ex. 2001-0001
`
`
`
`Our Approved Products I Corcept Therapeutics
`
`Page 2 of2
`
`Board of Directors
`
`Educational Grants
`
`Contact Us
`
`Research & Pipeline
`
`Cortisol Modulation
`
`Product
`Korlym for Cushing Syndrome
`
`Medical Information Request
`
`Patients
`
`Investors
`
`Investors Overview
`
`Cortisol Modulation Therapeutic Platform
`
`Press Releases
`
`Pipeline and Clinical Trials
`
`Publications
`
`Investigator-Initiated Studies
`
`Compassionate Use
`
`Careers
`
`Benefits
`
`Testimonials
`
`Current Opportunities
`
`Events
`
`Corporate Governance
`
`Analyst Coverage
`
`Stock Information
`
`SEC Filings
`
`© 2018 Corcept
`
`Privacy Policy
`
`Terms of Use
`
`Site Map
`
`https://www.corcept.com/product/
`
`11/19/2018
`Ex. 2001-0002
`
`
`
`Hypercortisolism (Cushing Syndrome) & Korlym® (mifepristone)
`
`Page 1 of 4
`
`Improving Measures
`That Matter
`
`Korlym® (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia
`secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who
`have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not
`candidates for surgery.
`
`Important Limitations of Use
`Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's
`syndrome.
`
`Learn More 7
`
`WHY KORLYM?
`
`ACCESSING KORL YM
`
`TAKING KORL YM
`
`Korlym helps decrease
`
`SPARK, the Support
`
`Learn what to expect when
`
`symptoms of excess
`
`Program for Access and
`
`you begin taking Korlym,
`
`including improvements in
`
`your sympfilffis~~E v
`
`reimbursement specialists
`
`common side effects.
`
`LWM...,,oreS
`KORLYM?
`
`M@ST IMPORTANT INFORMATION ABOUT
`KORL YM® (MIFEPRISTONE) 300 mg TABLETS
`
`https://www .korlym.com/
`
`11/19/2018
`Ex. 2001-0003
`
`
`
`Hypercortisolism (Cushing Syndrome) & Korlym® (mifepristone)
`
`Page 2 of 4
`
`are going through, a
`Patient Advocate is
`available to:
`
`» Provide one-on-
`one practical and
`emotional
`support
`» Answer your
`questions about
`hypercortisolism,
`how Korlym
`works, and what
`to expect from
`treatment
`» Help you prepare
`for discussions
`with your
`healthcare
`provider
`» Offer you regular
`IMPORTANT SAFETY INFORMATION ABOUT KORLYM,
`INCL9~~i~~RTANT WARNING ON LOSS OF
`PRE~furany
`
`SEE MORE v
`
`concerns you
`.MOST IMPORTANT INFORMATION ABOUT
`WHA,.lJ~
`KORtlffi?have dunWbRL YM® (MIFEPRISTONE) 300 mg TABLETS
`
`https://www .korlym.com/
`
`11/19/2018
`Ex. 2001-0004
`
`
`
`Hypercortisolism (Cushing Syndrome) & Korlym® (mifepristone)
`
`Page 3 of 4
`
`Learn More ~
`
`L _ - - - - -
`
`Learn More
`
`Learn More
`
`IMPORTANT SAFETY INFORMATION ABOUT KORLYM,
`INCLUDING IMPORTANT WARNING ON LOSS OF
`PREGNANCY.
`
`SEE MORE v
`
`WHAT IS
`KORLYM?
`
`MOST IMPORTANT INFORMATION ABOUT
`KORL YM® (MIFEPRISTONE) 300 mg TABLETS
`
`https://www .korlym.com/
`
`11/19/2018
`Ex. 2001-0005
`
`
`
`Hypercortisolism (Cushing Syndrome) & Korlym® (mifepristone)
`
`Page 4 of 4
`
`Korlym® is a registered trademark of Corcept
`
`Therapeutics lncorporated.©2018 Corcept
`
`Therapeutics Incorporated. All Rights Reserved.
`
`~[p~KOR-00561 MAY 2018
`
`Contact Us
`
`Privacy Policy
`
`Site Map
`
`IMPORTANT SAFETY INFORMATION ABOUT KORLYM,
`INCLUDING IMPORTANT WARNING ON LOSS OF
`PREGNANCY.
`
`SEE MORE v
`
`WHAT IS
`KORLYM?
`
`MOST IMPORTANT INFORMATION ABOUT
`KORL YM® (MIFEPRISTONE) 300 mg TABLETS
`
`https://www .korlym.com/
`
`11/19/2018
`Ex. 2001-0006
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
